CL2008003054A1 - Compuestos derivados de imidazolina-2,4-diona; procedimiento de preparacion; composicion farmaceutica y; su uso tratar, prevenir o retrasar el progreso de una condicion, enfermedad o desorden que puede ser modulado por repectores npy y2. - Google Patents

Compuestos derivados de imidazolina-2,4-diona; procedimiento de preparacion; composicion farmaceutica y; su uso tratar, prevenir o retrasar el progreso de una condicion, enfermedad o desorden que puede ser modulado por repectores npy y2.

Info

Publication number
CL2008003054A1
CL2008003054A1 CL2008003054A CL2008003054A CL2008003054A1 CL 2008003054 A1 CL2008003054 A1 CL 2008003054A1 CL 2008003054 A CL2008003054 A CL 2008003054A CL 2008003054 A CL2008003054 A CL 2008003054A CL 2008003054 A1 CL2008003054 A1 CL 2008003054A1
Authority
CL
Chile
Prior art keywords
npy
disorder
modulated
progress
disease
Prior art date
Application number
CL2008003054A
Other languages
English (en)
Inventor
Nozulak
Y Orain Joachim
David
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2008003054A1 publication Critical patent/CL2008003054A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/80—Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos heterociclios derivados de imidazolina, procedimiento de preparación, composición farmacéutica, combinación farmacéutica, útiles para tratar, prevenir o retrasar el progreso de una condición, enfermedad o desorden que puede ser modulado por repectores NPY Y2.
CL2008003054A 2007-10-16 2008-10-16 Compuestos derivados de imidazolina-2,4-diona; procedimiento de preparacion; composicion farmaceutica y; su uso tratar, prevenir o retrasar el progreso de una condicion, enfermedad o desorden que puede ser modulado por repectores npy y2. CL2008003054A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07118602 2007-10-16

Publications (1)

Publication Number Publication Date
CL2008003054A1 true CL2008003054A1 (es) 2009-05-15

Family

ID=39111624

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003054A CL2008003054A1 (es) 2007-10-16 2008-10-16 Compuestos derivados de imidazolina-2,4-diona; procedimiento de preparacion; composicion farmaceutica y; su uso tratar, prevenir o retrasar el progreso de una condicion, enfermedad o desorden que puede ser modulado por repectores npy y2.

Country Status (9)

Country Link
US (1) US20090099243A1 (es)
EP (1) EP2212314A1 (es)
JP (1) JP2011500632A (es)
CN (1) CN101827840A (es)
AR (1) AR068784A1 (es)
CL (1) CL2008003054A1 (es)
PE (1) PE20090967A1 (es)
TW (1) TW200927747A (es)
WO (1) WO2009050200A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090818A1 (es) * 2007-10-16 2009-07-24 Novartis Ag Compuestos heterociclicos como moduladores de los receptores de npy y2
US8779157B2 (en) 2009-09-04 2014-07-15 Vanderbilt University MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104000816B (zh) * 2014-05-28 2016-03-30 中山大学 二氧代咪唑烷-酰胺类化合物在制备抗hiv-1病毒药物中的应用
JP2024502056A (ja) * 2020-12-31 2024-01-17 上海医薬集団股▲分▼有限公司 ＲＯＲγｔモジュレーター、その製造方法および応用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
EP0640594A1 (en) * 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
US7317025B2 (en) * 2003-09-24 2008-01-08 Johnson & Johnson Pharmaceutical Research & Development, Llc Non-peptidic NPY Y2 receptor inhibitors
WO2005090316A1 (en) * 2004-03-12 2005-09-29 Wyeth HYDANTOINS HAVING RNase MODULATORY ACTIVITY
DK1899325T3 (da) * 2005-06-23 2012-03-05 Janssen Pharmaceutica Nv Imidazolinon- og hydantoinderivater som hidtil ukendte hæmmere af histondeacetylase
TW200730523A (en) * 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
PE20090818A1 (es) * 2007-10-16 2009-07-24 Novartis Ag Compuestos heterociclicos como moduladores de los receptores de npy y2

Also Published As

Publication number Publication date
CN101827840A (zh) 2010-09-08
AR068784A1 (es) 2009-12-02
US20090099243A1 (en) 2009-04-16
JP2011500632A (ja) 2011-01-06
EP2212314A1 (en) 2010-08-04
PE20090967A1 (es) 2009-08-10
TW200927747A (en) 2009-07-01
WO2009050200A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
CL2008001201A1 (es) Compuestos derivados de imidazol, triazol y/o piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hipertension o insuficiencia cardiaca.
ECSP099500A (es) Compuestos y composiciones como inhibidores de proteína quinasa
AR065721A1 (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa. composiciones farmaceuticas.
BRPI0909768A2 (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
CL2008001049A1 (es) Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad.
AR071003A1 (es) Farmaco contra cancer de higado
UY33397A (es) Forma sólida de un naftaleno carboxamida
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
CL2012003643A1 (es) Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension.
MX2009011002A (es) Composiciones de proteccion de isquemia/reperfusion y metodos de uso.
HN2010002733A (es) Compuestos y composiciones como inhibidores de cinasa
BRPI0922364A2 (pt) Composto, composição farmacêutica e uso de um composto
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2008003653A1 (es) Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
EA201790882A1 (ru) Способы и композиции для терапии рака печени
CL2008000029A1 (es) Compuestos derivados de 1-bencil imidazol, inhibidores de eg-5; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2011000604A1 (es) Compuestos derivados de multiheteroarilo, inhibidores de h-pgds, composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades inflamatorias y alergicas.
CR11290A (es) Derivados de ciclopropilamida
CL2010001361A1 (es) Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension.
CL2008002871A1 (es) Compuestos derivados de oxadiazol-bencimidazol; composicion farmaceutica que los contiene y su uso como inhibidores de dgt1 para el tratamiento de la tolerancia deteriorada a la glucosa, diabetes tipo 2 y obesidad.
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.
CL2007002329A1 (es) Compuestos derivados de 5,6-bisaril-2-piridin carboxamida, inhibidores de urotensina ii; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar y/o prevenir insuficiencia cardiaca congestiva, is